NASDAQ:BRKR - Bruker Stock Price, News, & Analysis

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker announced a quarterly dividend on Monday, August 13th. Stockholders of record on Tuesday, September 4th will be given a dividend of $0.04 per share on Friday, September 21st. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Friday, August 31st. View Bruker's Dividend History.

Bruker announced that its board has approved a stock buyback program on Sunday, June 4th 2017, which allows the company to buyback $225,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

Bruker Co. (NASDAQ:BRKR) posted its quarterly earnings results on Thursday, August, 2nd. The medical research company reported $0.25 EPS for the quarter, meeting the consensus estimate of $0.25. The medical research company had revenue of $443.70 million for the quarter, compared to the consensus estimate of $436.10 million. Bruker had a net margin of 4.99% and a return on equity of 27.03%. The company's quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.23 earnings per share. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Bruker.

Bruker updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share (EPS) guidance of $1.34-1.38 for the period, compared to the Thomson Reuters consensus estimate of $1.38. The company issued revenue guidance of approx $1.88 billion, compared to the consensus revenue estimate of $1.88 billion.

9 equities research analysts have issued 12-month price objectives for Bruker's shares. Their forecasts range from $24.00 to $42.00. On average, they expect Bruker's stock price to reach $33.1111 in the next twelve months. This suggests that the stock has a possible downside of 3.6%. View Analyst Price Targets for Bruker.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bruker.

Some companies that are related to Bruker include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), PerkinElmer (PKI), Bio-Rad Laboratories, Inc. Class B (BIO.B), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT) and HTG Molecular Diagnostics (HTGM).

Press coverage about BRKR stock has trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bruker earned a media and rumor sentiment score of 0.20 on Accern's scale. They also gave news coverage about the medical research company an impact score of 46.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Bruker.

Bruker's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (4.76%), BlackRock Inc. (3.43%), Acadian Asset Management LLC (3.02%), Millennium Management LLC (0.82%), Epoch Investment Partners Inc. (0.72%) and Dimensional Fund Advisors LP (0.62%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Acadian Asset Management LLC, First Trust Advisors LP, Sensato Investors LLC, Janus Henderson Group PLC, First Quadrant L P CA, Eagle Asset Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Bruker.

BRKR stock was bought by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Citadel Advisors LLC, Fuller & Thaler Asset Management Inc., Los Angeles Capital Management & Equity Research Inc., Point72 Asset Management L.P., Millennium Management LLC, CWM LLC and MUFG Securities EMEA plc. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $34.36.

Bruker has a market capitalization of $5.30 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]